Sectors & IndustriesHealthcareDrug Manufacturers - General

Best General Drug Manufacturer Stocks to Buy Now (2024)

Top general drug manufacturer stocks in 2024 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

Gilead Sciences (NASDAQ:GILD) is the top general drug manufacturer stock with a Zen Score of 60, which is 19 points higher than the general drug manufacturer industry average of 41. It passed 21 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock lose -21.88% over the past year, underperforming other general drug manufacturer stocks by -35 percentage points.

Gilead Sciences has an average 1 year price target of $80.75, an upside of 23.43% from Gilead Sciences's current stock price of $65.42.

Gilead Sciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Gilead Sciences, 16.67% have issued a Strong Buy rating, 8.33% have issued a Buy, 75% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Johnson & Johnson (NYSE:JNJ) is the second best general drug manufacturer stock with a Zen Score of 60, which is 19 points higher than the general drug manufacturer industry average of 41. It passed 22 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock lose -10.13% over the past year, underperforming other general drug manufacturer stocks by -23 percentage points.

Johnson & Johnson has an average 1 year price target of $176.88, an upside of 21.03% from Johnson & Johnson's current stock price of $146.14.

Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Johnson & Johnson, 37.5% have issued a Strong Buy rating, 25% have issued a Buy, 37.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Astrazeneca (NASDAQ:AZN) is the third best general drug manufacturer stock with a Zen Score of 52, which is 11 points higher than the general drug manufacturer industry average of 41. It passed 19 out of 38 due diligence checks and has strong fundamentals. Astrazeneca has seen its stock return 2.06% over the past year, underperforming other general drug manufacturer stocks by -11 percentage points.

Astrazeneca has an average 1 year price target of $83.50, an upside of 11.08% from Astrazeneca's current stock price of $75.17.

Astrazeneca stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Astrazeneca, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 12 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

Pfizer (NYSE:PFE) has an annual dividend yield of 6.5%, which is 3 percentage points higher than the general drug manufacturer industry average of 3.4%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 434.2% indicates that its high dividend yield might not be sustainable for the long-term.

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 5.22%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.4%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of -75.7% indicates that its high dividend yield might not be sustainable for the long-term.

Gilead Sciences (NASDAQ:GILD) has an annual dividend yield of 4.62%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.4%. Gilead Sciences's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Gilead Sciences's dividend has shown consistent growth over the last 10 years.

Gilead Sciences's dividend payout ratio of 66.1% indicates that its high dividend yield is sustainable for the long-term.

General drug manufacturer stocks were up 0.34% in the last day, and up 1.38% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

Biogen (NASDAQ:BIIB) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Biogen has a valuation score of 86, which is 43 points higher than the general drug manufacturer industry average of 43. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -27.48% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -40 percentage points.

Sanofi (NASDAQ:SNY) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Sanofi has a valuation score of 86, which is 43 points higher than the general drug manufacturer industry average of 43. It passed 6 out of 7 valuation due diligence checks.

Sanofi's stock has dropped -12.61% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -25 percentage points.

Gsk (NYSE:GSK) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Gsk has a valuation score of 71, which is 28 points higher than the general drug manufacturer industry average of 43. It passed 5 out of 7 valuation due diligence checks.

Gsk's stock has gained 14.42% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 2 percentage points.